Out-of-pocket costs for PARP inhibitors high in US Medicare beneficiaries with ovarian cancer

    This is a preview of subscription content, access via your institution.

    Reference

    1. Liang MI, et al. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. Gynecologic Oncology : 27 Dec 2020. Available from: URL: http://doi.org/10.1016/j.ygyno.2020.12.015

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Out-of-pocket costs for PARP inhibitors high in US Medicare beneficiaries with ovarian cancer. PharmacoEcon Outcomes News 870, 20 (2021). https://doi.org/10.1007/s40274-021-7423-7

    Download citation